Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.57 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676419 | 0.89 | ELANE (0.58) | ELANEPTGER4L3MBTL1NR4A2SMN1; SMN2 | |
| SCHEMBL29122000 | 0.89 | ELANE (0.58) | ELANEPTGER4L3MBTL1NR4A2LMNA | |
| SCHEMBL29122252 | 0.89 | ELANE (0.58) | ELANEPTGER4L3MBTL1NR4A2SMN1; SMN2 | |
| SCHEMBL29122008 | 0.86 | ELANE (0.56) | ELANESMN1; SMN2 | |
| SCHEMBL31584466 | 0.86 | ELANE (0.46) | ELANEPTGER4HCAR3KDM4CF2 | |
| SCHEMBL29121525 | 0.86 | ELANE (0.60) | ELANEPTGER4L3MBTL1NR4A2LMNA | |
| SCHEMBL25930827 | 0.84 | ELANE (0.58) | ELANEIDO1L3MBTL1NR4A2F2 | |
| SCHEMBL29121991 | 0.82 | ELANE (0.57) | ELANEKDM4CL3MBTL1NR4A2SMN1; SMN2 | |
| SCHEMBL18525606 | 0.82 | ELANE (0.52) | ELANEPTGER4L3MBTL1NR4A2SMN1; SMN2 | |
| SCHEMBL18526221 | 0.82 | ELANE (0.52) | ELANEPTGER4IDO1L3MBTL1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783522-B2 | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044133-A1 | NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF | ENPP2, ATXN2, ATXN2L | ELANE 415/4885PTGER4 3566/4885IDO1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.